

Madhav Dhodapkar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6343114/publications.pdf>

Version: 2024-02-01

33
papers

1,243
citations

623734

14
h-index

610901

24
g-index

33
all docs

33
docs citations

33
times ranked

1954
citing authors

#	ARTICLE	IF	CITATIONS
1	Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. <i>Journal of Experimental Medicine</i> , 2007, 204, 831-840.	8.5	175
2	Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). <i>Blood</i> , 2014, 123, 78-85.	1.4	173
3	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1928-1937.	1.6	148
4	Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. <i>Nature Medicine</i> , 2016, 22, 1351-1357.	30.7	132
5	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. <i>Nature Communications</i> , 2019, 10, 1911.	12.8	109
6	Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy. <i>JCI Insight</i> , 2019, 4, .	5.0	107
7	Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. <i>Blood</i> , 2015, 125, 4042-4051.	1.4	103
8	REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 41-42.	1.4	48
9	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). <i>Haematologica</i> , 2015, 100, 1214-1221.	3.5	44
10	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3057-3064.	1.6	31
11	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
12	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3020-3031.	1.6	26
13	How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2021, 2, 562-567.	5.0	22
14	Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19. <i>Blood Cancer Discovery</i> , 2021, 2, 9-12.	5.0	20
15	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. <i>Journal of Clinical Oncology</i> , 2022, 40, 3808-3816.	1.6	19
16	Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. <i>Blood Advances</i> , 2021, 5, 1535-1539.	5.2	17
17	Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention. <i>Frontiers in Immunology</i> , 2021, 12, 632564.	4.8	8
18	Downregulation of PA28 β induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 125.	6.2	7

#	ARTICLE	IF	CITATIONS
19	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. <i>Leukemia</i> , 2022, 36, 591-595.	7.2	6
20	Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 75.e1-75.e7.	1.2	5
21	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	5
22	Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. <i>Clinical Cancer Research</i> , 2020, 26, 5814-5819.	7.0	4
23	Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. <i>Leukemia</i> , 2021, 35, 3319-3323.	7.2	4
24	Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , 2020, 136, 28-29.	1.4	2
25	Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 17-18.	1.4	1
26	Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients. <i>Blood</i> , 2021, 138, 1616-1616.	1.4	0
27	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. <i>Blood</i> , 2021, 138, 1624-1624.	1.4	0
28	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , 2021, 138, 2691-2691.	1.4	0
29	Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma. <i>Blood</i> , 2020, 136, 20-22.	1.4	0
30	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
31	Role of clonoSEQ®, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 50-51.	1.4	0
32	Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data. <i>Blood</i> , 2020, 136, 15-15.	1.4	0
33	Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study. <i>Blood</i> , 2020, 136, 6-8.	1.4	0